Literature DB >> 3018749

Recombinant murine retroviruses containing avian v-myc induce a wide spectrum of neoplasms in newborn mice.

H C Morse, J W Hartley, T N Fredrickson, R A Yetter, C Majumdar, J L Cleveland, U R Rapp.   

Abstract

NFS/N mice were infected within 48 hr of birth with pseudotypes of recombinant murine leukemia viruses containing avian v-myc developed T-cell, pre-B-cell, and B-cell lymphomas and epithelial tumors including pancreatic and mammary adenocarcinomas. Primary hematopoietic and epithelial tumors and continuous in vitro cell lines derived from some of these tumors, established in the absence of added growth factors, exhibited clonal integrations of v-myc and expressed v-myc RNA. These results show that deregulated expression of the myc oncogene in mammalian cells can initiate a wide variety of neoplasms.

Entities:  

Mesh:

Year:  1986        PMID: 3018749      PMCID: PMC386611          DOI: 10.1073/pnas.83.18.6868

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  XenCSA: cell surface antigens related to the major glycoproteins (gp70) of xenotropic murine leukemia viruses.

Authors:  H C Morse; T M Chused; M Boehm-Truitt; B J Mathieson; S O Sharrow; J W Hartley
Journal:  J Immunol       Date:  1979-02       Impact factor: 5.422

2.  Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose.

Authors:  P S Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

3.  Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis.

Authors:  W S Hayward; B G Neel; S M Astrin
Journal:  Nature       Date:  1981-04-09       Impact factor: 49.962

4.  Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma.

Authors:  K Alitalo; M Schwab; C C Lin; H E Varmus; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

5.  The HL-60 transforming sequence: a ras oncogene coexisting with altered myc genes in hematopoietic tumors.

Authors:  M J Murray; J M Cunningham; L F Parada; F Dautry; P Lebowitz; R A Weinberg
Journal:  Cell       Date:  1983-07       Impact factor: 41.582

6.  Naturally occurring murine leukemia viruses in wild mice: characterization of a new "amphotropic" class.

Authors:  J W Hartley; W P Rowe
Journal:  J Virol       Date:  1976-07       Impact factor: 5.103

7.  Different lymphoid cell targets by transformation by replication-competent Moloney and Rauscher mouse leukemia viruses.

Authors:  E P Reddy; C Y Dunn; S A Aaronson
Journal:  Cell       Date:  1980-03       Impact factor: 41.582

8.  Increased expression of myc-related oncogene mRNA characterizes most BALB/c plasmacytomas induced by pristane or Abelson murine leukemia virus.

Authors:  J F Mushinski; S R Bauer; M Potter; E P Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  1983-02       Impact factor: 11.205

9.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

10.  The effect of helper virus on Abelson virus-induced transformation of lymphoid cells.

Authors:  N Rosenberg; D Baltimore
Journal:  J Exp Med       Date:  1978-04-01       Impact factor: 14.307

View more
  12 in total

1.  Cooperative transforming activities of ras, myc, and src viral oncogenes in nonestablished rat adrenocortical cells.

Authors:  A MacAuley; T Pawson
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

2.  raf/myc-infected erythroid cells are restricted in their ability to terminally differentiate.

Authors:  S P Klinken; U R Rapp; H C Morse
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

3.  The TCA cycle transferase DLST is important for MYC-mediated leukemogenesis.

Authors:  N M Anderson; D Li; H L Peng; F J F Laroche; M R Mansour; E Gjini; M Aioub; D J Helman; J E Roderick; T Cheng; I Harrold; Y Samaha; L Meng; A Amsterdam; D S Neuberg; T T Denton; T Sanda; M A Kelliher; A Singh; A T Look; H Feng
Journal:  Leukemia       Date:  2016-02-15       Impact factor: 11.528

4.  Properties of a murine retroviral recombinant of avian acute leukemia virus E26: a murine fibroblast assay for v-ets function.

Authors:  C C Yuan; N Kan; K J Dunn; T S Papas; D G Blair
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

5.  Susceptibility to raf and raf/myc retroviruses is governed by different genetic loci.

Authors:  S P Klinken; J W Hartley; T N Fredrickson; U R Rapp; H C Morse
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

6.  Tumorigenic potential of a myc-containing strain of feline leukemia virus in vivo in domestic cats.

Authors:  L S Levy; R E Fish; G B Baskin
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

7.  Transformation of murine bone marrow cells with combined v-raf-v-myc oncogenes yields clonally related mature B cells and macrophages.

Authors:  M Principato; J L Cleveland; U R Rapp; K L Holmes; J H Pierce; H C Morse; S P Klinken
Journal:  Mol Cell Biol       Date:  1990-07       Impact factor: 4.272

8.  An altered v-raf is required in addition to v-myc in J3V1 virus for acceleration of murine plasmacytomagenesis.

Authors:  J Troppmair; M Potter; J S Wax; U R Rapp
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

9.  Insertional mutagenesis of flvi-2 in tumors induced by infection with LC-FeLV, a myc-containing strain of feline leukemia virus.

Authors:  L S Levy; P A Lobelle-Rich
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

10.  Histogenesis and clonality of pancreatic tumors induced by v-myc and v-raf oncogenes in NFS/N mice.

Authors:  T N Fredrickson; J W Hartley; N K Wolford; J H Resau; U R Rapp; H C Morse
Journal:  Am J Pathol       Date:  1988-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.